A weekly injection for weight loss that combines semaglutide (Ozempic) with another appetite-reducing medication has helped adults lose an average of 20% of their bodyweight in an international…
A weekly injection for weight loss that combines semaglutide (Ozempic) with another appetite-reducing medication has helped adults lose an average of 20% of their bodyweight in an international trial. CagriSema combines semaglutide with cagrilintide, and the researchers tested this medication at two different dosages against an inactive placebo for 68 weeks in a group of 309 adults without diabetes.
Among the participants who finished the study, the researchers say those on the lower dose lost an average of 21% of their body weight, those on the higher dose lost 20.7% on average, and those on placebo lost an average of 2%. The researchers say increasing the weight loss options available for people is important to provide flexible, individualised options for people looking to lose weight.
This is a source-linked briefing. Read the original report from Science Media Exchange .